Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Neuroendovascular Coil Market Size & Share 2026-2035
Report ID: GMI14006
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Neuroendovascular Coil Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Neuroendovascular Coil Market Size
The Neuroendovascular Coil Market was valued at USD 1.04 billion in 2025, is projected to reach USD 1.10 billion in 2026, is expected to grow at a 6.0% CAGR (2026-2035), and is forecast to reach USD 1.86 billion by 2035.
Neuroendovascular Coil Market Key Takeaways
Market Leader: Stryker led with over 29% market share in 2025.
Leading Players: Top 5 players in this market include Terumo, Medtronic, Penumbra, Balt, Stryker, which collectively held a market share of 61% in 2025.
The market encompasses catheter-delivered coils used to occlude intracranial aneurysms, arteriovenous malformations, and related neurovascular lesions. Demand is increasingly shaped by earlier lesion identification, the clinical migration toward minimally invasive treatment, and a mix shift toward differentiated coil technologies that can support revenue per procedure even where case growth is measured.
GMI Analyst View
Our primary discussions with hospital procurement directors and interventional neuroradiologists indicate that the market reached USD 985 million in 2024. We see the subsequent migration toward hydrogel and bioactive platforms supporting average selling price resilience as tertiary neurovascular centers place greater weight on recurrence management and procedural performance.
Neuroendovascular Coil Market Trends, Growth Drivers & GMI Forecast Outlook
The outlook rests on a durable clinical demand base rather than a simple procedure-volume expansion story. Earlier aneurysm detection and aging-related cerebrovascular exposure increase the treated population, while premium coil adoption raises the revenue intensity of eligible procedures. Recurrence concerns, reimbursement discipline, and specialist-capacity constraints keep growth calibrated.
Key Drivers
*Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.* Disease burden is commercially relevant because rupture events require immediate intervention and because wider imaging access identifies lesions before rupture, when treatment can be planned through established neurovascular pathways. This broadens the addressable procedure base beyond emergency treatment and reinforces routine replenishment demand for coil inventories at capable centers.
Population aging compounds that effect. Older patients are more likely to present with the risk factors associated with aneurysm formation and rupture, but the market opportunity depends on the ability of hospitals to convert clinical identification into treatment through imaging, specialist referral, and catheter-laboratory access. Mature systems benefit from these links already being in place; developing systems are building them unevenly.
Product innovation affects market value as well as clinical choice. Polymer-expanded and bioactive designs are adopted where physicians and value-analysis committees consider improved conformability, packing density, or recurrence management sufficient to justify a premium. Their diffusion therefore depends on evidence, clinician familiarity, reimbursement, and the availability of delivery systems suited to complex anatomy.
Key Restraints
*Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.* Recurrence creates a mixed commercial outcome. Retreatment can generate incremental device demand, but it also focuses clinical scrutiny on occlusion durability and increases payer sensitivity to the total cost of care. The result is a stronger rationale for differentiated coils in anatomies where outcomes evidence is compelling, rather than an uncomplicated increase in coil volume.
Procedure economics are especially restrictive for elective treatment in systems with limited insurance coverage or fixed public reimbursement. Emergency rupture management remains clinically prioritized, whereas unruptured aneurysm intervention is more exposed to budget limits, referral delays, and hospital capital-allocation decisions. Infrastructure constraints add a second bottleneck because device availability alone cannot establish a coiling program without trained operators, imaging capacity, neuroanesthesia, and post-procedure support.
GMI Analyst View
We view the central forecasting tension as the interaction between expanding clinical eligibility and uneven affordability. Premiumization can preserve revenue momentum where reimbursement recognizes differentiated performance, but capacity and funding constraints will determine how much latent demand becomes completed treatment, particularly outside established neurovascular systems.
Neuroendovascular Coil Market Segment Analysis
By Type
Bare Platinum Coils
Bare platinum coils generated USD 676 million in 2025 and are projected to account for 52% of the market by 2035. Bare platinum remains the practical foundation of coil procurement because it is familiar to physicians, broadly compatible with established procedural workflows, and economically accessible in high-volume or budget-sensitive settings. Its relative revenue position changes as differentiated products secure a larger role in complex and recurrence-sensitive cases, not because the category loses its core framing and finishing functions.
Hydrogel-Coated Coils
Hydrogel-coated coils are forecast to generate USD 764 million by 2035 and are expected to grow at a 7.8% CAGR (2026-2035). The segment's momentum reflects the value placed on packing performance and on strategies intended to manage recanalization risk. Adoption is strongest where purchasing committees can evaluate clinical evidence alongside device cost, allowing premium formulations to move beyond flagship academic programs into broader neurovascular practice.
Other Types
Other coil types accounted for 7% of market revenue in 2025 and are forecast to reach USD 130 million by 2035. Fibered, bioactive, and specialized geometry designs serve anatomies in which conventional helical constructs may be less effective or less efficient. Their role is narrow in aggregate but meaningful in complex intervention, where procedural customization and physician preference can outweigh standardized purchasing criteria.
By Application
Intracranial Aneurysms
Intracranial aneurysms represented 78% of global coil revenue in 2025 and are forecast to generate USD 1.42 billion by 2035. Aneurysm treatment remains the market's principal clinical anchor because coiling is embedded in emergency and elective care pathways for a broad range of lesion profiles. Demand is reinforced by imaging-led diagnosis, established referral networks, and the need for devices that can be selected across varied aneurysm sizes, neck configurations, and rupture status.
Arteriovenous Malformations
Arteriovenous malformations are forecast to generate USD 279 million by 2035 and are expected to grow at a 6.5% CAGR (2026-2035).
In AVM procedures, coils are commonly used within a multimodal treatment approach that can also involve liquid embolics, surgery, or radiosurgery. This makes purchasing decisions more procedure-specific than in aneurysm coiling and positions coils as part of a broader strategy to manage feeding vessels, flow dynamics, and staged intervention.
Other Applications
Other applications held an 8% market share in 2025 and are projected to grow at a 7.0% CAGR (2026-2035). This category includes uses such as dural arteriovenous fistulas and selected tumor-devitalization procedures, where specialized coil configurations can address discrete procedural needs. Its growth is linked to the expansion of neurointerventional expertise and to the continued formalization of treatment protocols beyond the largest established indications.
By End Use
Hospitals
Hospitals generated USD 780 million in 2025 and are projected to hold a 68% share by 2035. The Neuroendovascular Coil Market remains anchored in hospitals because ruptured aneurysm care requires immediate access to imaging, catheterization capability, neuroanesthesia, intensive care, and multidisciplinary neurological support. Tertiary and academic facilities are also early adopters of new platforms, which makes hospital procurement central to product evaluation and clinical diffusion.
Ambulatory Surgical Centers
Ambulatory surgical centers are forecast to generate USD 317 million by 2035 and are expected to grow at an 8.2% CAGR (2026-2035). ASC demand depends on careful patient selection, regulatory authorization, and reimbursement structures that recognize outpatient neurovascular care. Where those conditions are met, the channel can offer a more efficient setting for selected elective procedures, creating a distinct purchasing environment focused on throughput, scheduling, and total episode cost.
Specialty Clinics
Specialty clinics accounted for 8% of market revenue in 2025 and are projected to grow at a 7.2% CAGR (2026-2035). These practices can concentrate referral relationships and neurointerventional expertise in urban markets, particularly for planned procedures. Their influence on coil demand is tied less to standalone procedure volume than to their role in diagnostics, treatment planning, follow-up, and the channeling of patients toward affiliated procedural facilities.
Academic & Research Institutes
Academic and research institutes are forecast to generate USD 93 million by 2035 and accounted for 5% of market revenue in 2025. Although their purchasing footprint is smaller, these institutions influence platform adoption through clinical trials, physician training, registry participation, and early evaluation of new coil technologies. Manufacturers seeking clinical credibility often depend on this setting to establish evidence and practical familiarity before wider commercial rollout.
GMI Analyst View
We see mix migration, rather than a uniform rise in every coil category, as the defining segment outcome. Clinical evidence and procedural complexity will continue to separate premium coil adoption from commodity procurement, while the outpatient channel's development will depend on policy and operational readiness as much as on physician demand.
Neuroendovascular Coil Market Regional Analysis
North America Neuroendovascular Coil Market Analysis
North America generated USD 390 million in 2025 and is forecast to reach USD 648 million by 2035. The Neuroendovascular Coil Market in North America benefits from deep specialist capacity, established reimbursement pathways, and access to a broad choice of coil and delivery technologies. Growth increasingly reflects product substitution and service-channel evolution rather than the creation of basic neurovascular treatment capacity.
United States
The United States is forecast to generate USD 584 million by 2035 and is expected to grow at a 5.5% CAGR (2026-2035). The market is supported by a mature neurointerventional workforce, robust tertiary-care networks, and reimbursement conditions that can support differentiated coil platforms. U.S. providers also represent a leading early-adoption base for products entering through FDA clearance pathways.
Canada
Canada is forecast to generate USD 64 million by 2035 and is expected to grow at a 5.0% CAGR (2026-2035). Provincial procurement and health technology assessment shape the pace at which premium products enter routine use. Large specialist centers remain the primary demand nodes, with purchasing decisions balancing clinical requirements against public-system budget discipline.
Europe Neuroendovascular Coil Market Analysis
Europe represented a 26.7% share of the global market in 2025 and is expected to grow at a 5.5% CAGR (2026-2035). European demand is underpinned by a mature hospital procedural base and well-developed neurovascular networks, but purchasing behavior differs by reimbursement structure, tendering practice, and the pace of premium-product acceptance. Western European systems provide an established platform for innovation, while capacity expansion in other markets creates additional volume opportunities.
Germany
Germany generated USD 60 million in 2025 and is forecast to reach USD 102 million by 2035. A broad hospital base and established neurological care infrastructure support consistent demand for standard and differentiated coil platforms. Academic centers remain influential in new product evaluation and in the integration of advanced coiling strategies into procedural practice.
United Kingdom
The United Kingdom is forecast to generate USD 84 million by 2035 and is expected to grow at a 5.3% CAGR (2026-2035). National procurement frameworks encourage price discipline, while regional neurovascular networks sustain procedure access for elective and emergency care. This environment favors suppliers that can pair clinical support with reliable tender execution and service coverage.
France
France generated USD 45 million in 2025 and is forecast to reach USD 74 million by 2035. The country's established interventional neuroradiology base supports demand across university hospital systems and major referral centers. Competitive positioning depends on navigating institutional purchasing structures while demonstrating value in sophisticated neurovascular practice.
Italy
Italy is forecast to generate USD 60 million by 2035 and generated USD 37 million in 2025. Regional variation in hospital investment and procurement produces an uneven market, although major centers sustain advanced endovascular programs. Suppliers must address both high-capability clinical hubs and the fragmented decision-making environment across regional health systems.
Spain
Spain is forecast to hold an 11.5% share within Europe by 2035 and is expected to grow at a 5.2% CAGR (2026-2035). Demand is concentrated in large university hospitals and established referral networks, where coiling procedures are integrated into specialist stroke and neurovascular services. Public procurement makes demonstrated clinical utility and competitive total-cost positioning particularly important.
Netherlands
The Netherlands is forecast to generate USD 33 million by 2035 and generated USD 20 million in 2025. Its organized specialist network and active research community provide an environment conducive to clinical evaluation and protocol-driven adoption. The market's strategic importance exceeds its absolute size because local clinical participation can influence broader European technology adoption.
Asia Pacific Neuroendovascular Coil Market Analysis
Asia Pacific is forecast to hold a 28.0% share of global revenue by 2035 and is expected to grow at a 7.5% CAGR (2026-2035). The Neuroendovascular Coil Market in Asia Pacific combines mature, high-procedure markets with countries expanding diagnostic capacity, physician training, and tertiary-care infrastructure. Demand progression is therefore heterogeneous: established systems prioritize product mix and reimbursement, whereas developing systems focus on building access to intervention itself.
China
China generated USD 85 million in 2025 and is forecast to hold a 26.8% share within Asia Pacific by 2035. The market combines expanding procedural capacity with procurement pressure from public-hospital purchasing rules and domestic competition. Standard coil tiers are especially exposed to price discipline, while premium adoption depends on hospitals' ability to differentiate technology value within controlled purchasing environments.
Japan
Japan is forecast to generate USD 112 million by 2035 and is expected to grow at a 4.0% CAGR (2026-2035). Japan's demand base is mature, supported by high specialist availability and established intervention pathways. National pricing controls and limited incremental capacity temper growth, but the country remains an important market for clinically validated devices and dependable supply.
India
India generated USD 40 million in 2025 and is expected to grow at a 12.0% CAGR (2026-2035). Private tertiary hospital expansion, greater insurance access, and specialist workforce development create a favorable long-term demand environment. Realized growth will nevertheless depend on the pace at which advanced neurovascular capability extends beyond leading metropolitan institutions.
South Korea
South Korea is forecast to hold a 15.1% share within Asia Pacific by 2035 and is expected to grow at a 7.0% CAGR (2026-2035). A coordinated stroke-care network and strong imaging availability support the integration of neurovascular intervention into acute and elective pathways. The market can support differentiated coil adoption where reimbursement and clinical practice align around advanced treatment protocols.
Australia
Australia accounted for a 7.7% share within Asia Pacific in 2025 and is forecast to generate USD 33 million by 2035. The market is supported by broad specialist access and a mixed public-private hospital structure. Its procurement environment accommodates both clinically driven premium adoption and cost-conscious purchasing, depending on provider setting and payer mix.
Latin America Neuroendovascular Coil Market Analysis
Latin America is forecast to generate USD 104 million by 2035 and is expected to grow at a 7.5% CAGR (2026-2035). Growth is concentrated in major urban tertiary-care systems, where specialist capacity and procedural infrastructure are sufficient to support regular coiling programs. Broader adoption is moderated by uneven reimbursement, economic volatility, and the limited distribution of trained neurointerventional teams outside major metropolitan areas.
Brazil
Brazil generated USD 30 million in 2025 and is expected to grow at an 8.0% CAGR (2026-2035). Private hospital networks are central to premium coil demand, while public procurement places greater emphasis on affordability in emergency treatment. Regulatory access and teaching-hospital capability support continued market development in the country's largest urban centers.
Mexico
Mexico is forecast to generate USD 23 million by 2035 and is expected to grow at a 7.5% CAGR (2026-2035). Demand is concentrated in large private hospitals and public institutions with advanced neurovascular programs. Expansion beyond these centers depends on reimbursement improvement and on the availability of specialist teams able to support complex catheter-based intervention.
Argentina
Argentina accounted for 11.5% of Latin American market revenue in 2025 and is expected to grow at a 6.0% CAGR (2026-2035). Academic hospitals in Buenos Aires remain the core demand base. Import exposure and macroeconomic instability can affect procurement timing, making distributor capability, inventory planning, and flexible commercial execution important to supplier performance.
Middle East & Africa Neuroendovascular Coil Market Analysis
The Middle East & Africa generated USD 60 million in 2025 and is expected to grow at an 8.0% CAGR (2026-2035). The region's outlook is tied to investment in tertiary-care infrastructure, imaging capacity, and specialist workforce development. Gulf markets are building advanced neurovascular services more rapidly, while many African systems remain constrained by equipment availability, referral pathways, and limited specialist density.
Saudi Arabia
Saudi Arabia generated USD 20 million in 2025 and is expected to grow at a 9.0% CAGR (2026-2035). Health-system modernization and specialist-center expansion support growing access to neurovascular intervention. The market's progression will depend on sustained implementation of hospital investment programs and on the development of referral networks that can channel eligible patients to advanced centers.
United Arab Emirates
The United Arab Emirates is forecast to generate USD 42 million by 2035 and is expected to grow at a 9.5% CAGR (2026-2035). A private-sector-oriented care system, concentrated medical hubs, and international clinician recruitment create favorable conditions for advanced device adoption. Demand can develop quickly where leading centers combine reimbursement access with the ability to establish comprehensive neurovascular programs.
South Africa
South Africa represented a 16.7% share within MEA in 2025 and is expected to grow at a 6.5% CAGR (2026-2035). Private tertiary networks provide the region's most established base for neurovascular intervention. Wider market development is limited by disparities in infrastructure and specialist availability between private and public healthcare settings.
GMI Analyst View
We expect regional performance to diverge according to a market's ability to translate clinical need into available procedure capacity. Mature markets will compete through technology adoption and channel optimization, whereas faster-growth geographies will be defined by infrastructure execution, specialist training, and the durability of reimbursement support.
Neuroendovascular Coil Market Share & Competitive Landscape
The Neuroendovascular Coil Market share is concentrated among established suppliers with entrenched physician relationships, broad embolization portfolios, clinical education capabilities, and the regulatory resources required to sustain product refresh cycles. The top five suppliers held approximately 90% of the global market in 2025, creating high qualification barriers while leaving room for focused challengers in premium technologies and regional channels.
Stryker held a 29% share in 2025. Its competitive position is supported by a broad neurovascular portfolio that links coils with access, delivery, and procedural-support systems, strengthening its relevance to hospital purchasing teams seeking consolidated clinical and commercial relationships. The FDA cleared Stryker Neurovascular's Target Detachable Coil under K252694 in December 2025 [5]U.S. Food and Drug Administration. “510(k) Premarket Notification - K252694, Target Detachable Coil, Stryker Neurovascular.” fda.gov.
Terumo Neuro held a 23% market share in 2025. Its position in polymer-expanded coil embolization gives it a strong role in procedures where clinicians prioritize packing characteristics and recurrence-related outcomes, while its broader neurovascular identity supports cross-portfolio engagement with specialist centers.
Medtronic held a 19% share in 2025. The company benefits from global commercial reach and from the ability to participate across coil, catheter, and procedural guidance ecosystems, which can be important where hospitals favor suppliers that provide integrated training and dependable device availability.
Penumbra and Balt remain consequential competitive participants through specialist neurovascular positioning, distribution reach, and targeted portfolio development. Their ability to gain share depends on differentiated clinical propositions, local commercial execution, and responsiveness to physician demand for products tailored to complex anatomy or evolving treatment workflows.
New entrants can exert pressure most readily in high-value niches rather than through broad commodity competition. MicroPort NeuroScientific's NUMEN™ Silk Coil Embolization System received FDA clearance in 2024, expanding the range of ultra-soft, electrolytically detachable polymer coil options available to U.S. providers. Stryker and Siemens Healthineers also announced a collaboration on neurovascular robotics, signaling interest in integrating device platforms with image-guided procedural workflow [6]MassDevice. “Siemens Healthineers, Stryker partner on neurovascular robotics.” massdevice.com.
Recent Industry Developments
December 2025: Stryker Neurovascular received FDA 510(k) clearance for the Target Detachable Coil under K252694, expanding its Target platform for neurovascular embolization applications.
September 2025: Stryker and Siemens Healthineers announced a collaboration focused on an integrated robotic neurovascular procedural platform spanning device integration, imaging, navigation, and workflow development.
September 2024: MicroPort NeuroScientific received FDA clearance for the NUMEN™ Silk Coil Embolization System, supporting its entry into the U.S. premium coil segment [7]MicroPort NeuroScientific. “MicroPort NeuroScientific Receives FDA Clearance for Its NUMEN™ Silk in the USA.” microport.com.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →